FDA Determines Regulatory Review Period for Rimadyl Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of Rimadyl, an animal drug product, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce.